American Society for Clinical Oncology 40th Annual Meeting, New Orleans, LA, 5–8 June 2004: breast cancer highlights

por Sundermeyer, Mark L, Goldstein, Lori J
Publicado 2004

Profile of abemaciclib and its potential in the treatment of breast cancer

por Martin, James M, Goldstein, Lori J
Publicado 2018

Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data

por Martin, James M, Handorf, Elizabeth A, Montero, Alberto J, Goldstein, Lori J
Publicado 2022

Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis

por O’Shaughnessy, Joyce, Cortes, Javier, Twelves, Chris, Goldstein, Lori J., Alexis, Karenza, Xie, Ran, Barrios, Carlos, Ueno, Takayuki
Publicado 2020

Racial inequities in second-line treatment and overall survival among patients with metastatic breast cancer

por Whitaker, Kristen D., Wang, Xiaoliang, Ascha, Mustafa, Showalter, Timothy N., Lewin, Heather G., Calip, Gregory S., Goldstein, Lori J.
Publicado 2022

Identifying Patients Who May Be Candidates for a Clinical Trial of Salvage Accelerated Partial Breast Irradiation after Previous Whole Breast Irradiation

por Li, Linna, Li, Tianyu, Cohen, Randi J., Anderson, Penny R., Goldstein, Lori J., Bleicher, Richard J., Freedman, Gary M.
Publicado 2012

Towards an immunoscore for triple negative breast cancer (TNBC): lymphocytic infiltrate predicts outcome

por Adams, Sylvia, Gray, Robert, Demaria, Sandra, Goldstein, Lori J, Perez, Edith A, Shulman, Lawrence N, Martino, Silvana, Davidson, Nancy E, Sledge, George W, Sparano, Joseph A, Badve, Sunil
Publicado 2013

Collagen fiber orientation disorder from H&E images is prognostic for early stage breast cancer: clinical trial validation

por Li, Haojia, Bera, Kaustav, Toro, Paula, Fu, PingFu, Zhang, Zelin, Lu, Cheng, Feldman, Michael, Ganesan, Shridar, Goldstein, Lori J., Davidson, Nancy E., Glasgow, Akisha, Harbhajanka, Aparna, Gilmore, Hannah, Madabhushi, Anant
Publicado 2021

A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer

por Goldstein, Lori J., Perez, Raymond P., Yardley, Denise, Han, Linda K., Reuben, James M., Gao, Hui, McCanna, Susan, Butler, Beth, Ruffini, Pier Adelchi, Liu, Yi, Rosato, Roberto R., Chang, Jenny C.
Publicado 2020

Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer

por Goldstein, Lori J., Perez, Raymond P., Yardley, Denise, Han, Linda K., Reuben, James M., Gao, Hui, McCanna, Susan, Butler, Beth, Ruffini, Pier Adelchi, Liu, Yi, Rosato, Roberto R., Chang, Jenny C.
Publicado 2020

A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast...

por Goldstein, Lori J., Mansutti, Mauro, Levy, Christelle, Chang, Jenny C., Henry, Stephanie, Fernandez-Perez, Isaura, Prausovà, Jana, Staroslawska, Elzbieta, Viale, Giuseppe, Butler, Beth, McCanna, Susan, Ruffini, Pier Adelchi, Wicha, Max S., Schott, Anne F.
Publicado 2021

A metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer

por Sparano, Joseph A., Gray, Robert, Oktay, Maja H., Entenberg, David, Rohan, Thomas, Xue, Xiaonan, Donovan, Michael, Peterson, Michael, Shuber, Anthony, Hamilton, Douglas A., D’Alfonso, Timothy, Goldstein, Lori J., Gertler, Frank, Davidson, Nancy E., Condeelis, John, Jones, Joan
Publicado 2017

Prospective Comparison of Geriatric Assessment and Provider’s Assessment of Older Adults With Metastatic Breast Cancer in the Community

por Seedor, Rino S, Meeker, Caitlin R, Lewis, Bianca, Handorf, Elizabeth A, Filchner, Kelly A, Varadarajan, Ramya, Hensold, Jack, Padmanabhan, Aruna, Negin, Benjamin, Blankstein, Kenneth, Chawla, Neha R, Song, Wei (Frank), Epstein, Jessica, Winn, Jennifer, Goldstein, Lori J, Dotan, Efrat
Publicado 2022

Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer

por Chen, Yuli, Li, Haojia, Janowczyk, Andrew, Toro, Paula, Corredor, Germán, Whitney, Jon, Lu, Cheng, Koyuncu, Can F., Mokhtari, Mojgan, Buzzy, Christina, Ganesan, Shridar, Feldman, Michael D., Fu, Pingfu, Corbin, Haley, Harbhajanka, Aparna, Gilmore, Hannah, Goldstein, Lori J., Davidson, Nancy E., Desai, Sangeeta, Parmar, Vani, Madabhushi, Anant
Publicado 2023

High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers

por Willis, Scooter, Sun, Yuliang, Abramovitz, Mark, Fei, Teng, Young, Brandon, Lin, Xiaoqian, Ni, Min, Achua, Justin, Regan, Meredith M., Gray, Kathryn P., Gray, Robert, Wang, Victoria, Long, Bradley, Kammler, Roswitha, Sparano, Joseph A., Williams, Casey, Goldstein, Lori J., Salgado, Roberto, Loi, Sherene, Pruneri, Giancarlo, Viale, Giuseppe, Brown, Myles, Leyland-Jones, Brian
Publicado 2017

Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study

por Turner, Nicholas C., Balmaña, Judith, Poncet, Coralie, Goulioti, Theodora, Tryfonidis, Konstantinos, Honkoop, Aafke H., Zoppoli, Gabriele, Razis, Evangelia, Johannsson, Oskar T., Colleoni, Marco, Tutt, Andrew N., Audeh, William, Ignatiadis, Michail, Mailliez, Audrey, Trédan, Olivier, Musolino, Antonino, Vuylsteke, Peter, Juan-Fita, Maria Jose, Macpherson, Iain R.J., Kaufman, Bella, Manso, Luis, Goldstein, Lori J., Ellard, Susan L., Láng, István, Jen, Kai Yu, Adam, Virginie, Litière, Saskia, Erban, John, Cameron, David A.
Publicado 2021